Bristol-Myers Tops Estimates, Helped by Higher Sales

undergone elective hip or knee replacement surgery. Bristol had one setback in February, when the company and partner Eli Lilly and Co. stopped enrollment of patients in one of two mid-stage studies of a drug for non-small cell lung cancer, necitumumab,...